These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 3631942)

  • 21. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1995)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kawaguchi H; Shimizu Y; Matsumiya H; Saito A; Terai T; Inoue H; Nakadate T; Ito C; Yosida T; Tanno Y; Ohno I; Nishioka K; Arakawa M; Igarashi K; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Touyama M
    Jpn J Antibiot; 1997 May; 50(5):421-59. PubMed ID: 9212366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus.
    Zinner SH; Klastersky J; Gaya H; Bernard C; Ryff JC
    Antimicrob Agents Chemother; 1981 Oct; 20(4):463-9. PubMed ID: 6282192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ciprofloxacin: in vitro, experimental, and clinical evaluation.
    Thadepalli H; Bansal MB; Rao B; See R; Chuah SK; Marshall R; Dhawan VK
    Rev Infect Dis; 1988; 10(3):505-15. PubMed ID: 3393781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bactericidal activity of ciprofloxacin against amikacin- and cefotaxime-resistant gram-negative bacilli and methicillin-resistant staphylococci.
    Simberkoff MS; Rahal JJ
    Antimicrob Agents Chemother; 1986 Jun; 29(6):1098-100. PubMed ID: 2942105
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of Ro 23-9424, a dual-action cephalosporin, compared with activities of other antibiotics.
    Gu JW; Neu HC
    Antimicrob Agents Chemother; 1990 Feb; 34(2):189-95. PubMed ID: 2327765
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin.
    Paradis D; Vallée F; Allard S; Bisson C; Daviau N; Drapeau C; Auger F; LeBel M
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2085-92. PubMed ID: 1444289
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bactericidal effects of levofloxacin in comparison with those of ciprofloxacin and sparfloxacin.
    Odenholt I; Löwdin E; Cars O
    Clin Microbiol Infect; 1998 May; 4(5):264-270. PubMed ID: 11864341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Susceptibilities of bacteria isolated from patients with respiratory infectious diseases to antibiotics (1994)].
    Ikemoto H; Watanabe K; Mori T; Igari J; Oguri T; Kobayashi K; Satou K; Matsumiya H; Saito A; Terai T; Tanno Y; Nishioka K; Arakawa M; Wada K; Okada M; Ozaki K; Aoki N; Kitamura N; Sekine O; Suzuki Y; Matsuda M; Tanimoto H; Nakata K; Nakamori Y; Kusano N
    Jpn J Antibiot; 1996 May; 49(5):419-55. PubMed ID: 8752860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro Activity of Sitafloxacin and Other Antibiotics against Bacterial Isolates from HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University and Samitivej Sukhumvit Hospital.
    Tantisiriwat W; Linasmita P
    J Med Assoc Thai; 2017 Apr; 100(4):469-78. PubMed ID: 29912484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1999)].
    Shimada K; Nakano K; Ohno I; Okada S; Hayashi K; Yokouchi H; Arakawa M; Gejyo F; Igarashi K; Ikemoto H; Mori T; Okada M; Ozaki K; Igari J; Aoki N; Oguri T; Kitamura N; Terai T; Suzuki Y; Inoue H; Nakadate T; Karasawa Y; Ito C; Yoshida T; Nakata K; Nakatani T; Inagawa H; Ando M; Suga M; Sato K; Kudo K; Kobayashi N; Tosaka M; Hasegawa M; Kohno S; Tomono K; Miyazaki Y; Kobayashi H; Kawai S; Takayasu S; Hirakata Y; Matsuda J; Mochida C; Ito A; Sumitomo M; Nasu M; Nagai H; Matsushima T; Niki Y; Hiramatsu K; Nakano T
    Jpn J Antibiot; 2001 Jul; 54(7):331-64. PubMed ID: 11560054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cefotaxime kinetics in plasma and synovial fluid following intravenous administration in horses.
    Orsini JA; Moate PJ; Engiles J; Norman T; Poppenga R; Benson CE; Boston RC
    J Vet Pharmacol Ther; 2004 Oct; 27(5):293-8. PubMed ID: 15500566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of ciprofloxacin against multiply resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, and group JK corynebacteria.
    Venezio FR; Tatarowicz W; DiVincenzo CA; O'Keefe JP
    Antimicrob Agents Chemother; 1986 Dec; 30(6):940-1. PubMed ID: 3101589
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative "in vitro" activity of ciprofloxacin (Bay o9867) and other antimicrobial agents against urinary bacterial isolates.
    Piccolomini R; Ravagnan G
    Chemioterapia; 1986 Aug; 5(4):249-56. PubMed ID: 3769047
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro and in vivo antibacterial activities of DK-507k, a novel fluoroquinolone.
    Otani T; Tanaka M; Ito E; Kurosaka Y; Murakami Y; Onodera K; Akasaka T; Sato K
    Antimicrob Agents Chemother; 2003 Dec; 47(12):3750-9. PubMed ID: 14638477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum bactericidal activity of ciprofloxacin and ofloxacin in volunteers.
    Machka K; Milatovic D
    Eur J Clin Microbiol; 1987 Feb; 6(1):59-62. PubMed ID: 3106034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of ciprofloxacin compared with other agents against recent hospital isolates.
    Rubinstein E; Mark Z; Samra Y; Alkan M; Berger S
    Chemioterapia; 1986 Apr; 5(2):75-82. PubMed ID: 2939966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of serum bactericidal activity after administration of cefoperazone, cefotaxime, ceftizoxime, and moxalactam to healthy subjects.
    Barriere SL; Ozasa DC; Mordenti J
    Antimicrob Agents Chemother; 1985 Jul; 28(1):55-7. PubMed ID: 3929680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative in vitro inhibitory and killing activity of cefpirome, ceftazidime, and cefotaxime against Pseudomonas aeruginosa, enterococci, Staphylococcus epidermidis, and methicillin-susceptible and -resistant and tolerant and nontolerant Staphylococcus aureus.
    Goldstein EJ; Citron DM
    Antimicrob Agents Chemother; 1985 Jul; 28(1):160-2. PubMed ID: 3929677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum bactericidal activity from intravenous ciprofloxacin and azlocillin given alone and in combination to healthy subjects.
    Orlando PL; Barriere SL; Hindler JA; Frost RW
    Diagn Microbiol Infect Dis; 1990; 13(2):93-7. PubMed ID: 2114954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar.
    Hyatt JM; Nix DE; Schentag JJ
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2730-7. PubMed ID: 7695254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.